<DOC>
	<DOCNO>NCT02464657</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose nivolumab give combination idarubicin cytarabine patient MDS AML . The safety effectiveness drug combination also study .</brief_summary>
	<brief_title>Study Idarubicin , Cytarabine , Nivolumab Patients With High-Risk Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 3 group 3 - 6 participant enrol Phase 1 study , 70 participant enrol Phase 2 . If enrolled Phase 1 , dose nivolumab receive depend join study . There 3 dose level test part study : low dose , middle dose , high dose . The first group participant receive middle dose level nivolumab . If intolerable side effect see , next group receive high dose level . However , intolerable side effect , 3 participant receive middle dose . If intolerable side effect see , next group receive low dose nivolumab . If enrolled Phase 2 , receive nivolumab high dose tolerate Phase 1 . All participant receive dose level idarubicin cytarabine . Study Drug Administration : You receive 1- 7 cycle drug combination . These cycle 28-35 day long . - On Days 1-3 cycle , receive idarubicin vein 1 hour . - On Days 1-4 cycle , receive cytarabine vein 24 hour . If age 60 old , receive drug Days 1-3 . On day receive drug help decrease risk side effect . - On Day 24 ( +/- 2 day ) cycle , receive nivolumab vein 1 hour . After 2 cycle , disease appear get good , receive nivolumab vein every 2 week 1 year . Study Visits : At least one ( 1 ) time week Cycle 1 least cycle : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . You bone marrow aspirate collect cytogenetics test Day 21-28 cycle , doctor think need , perform every 1-2 week unless complete response achieve . After , bone marrow collect every 3-6 month 1 year . After last dose study drug , physical exam . Length Study : You may continue take nivolumab 1 year . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . This investigational study . Nivolumab FDA-approved commercially available . Idarubicin FDA-approved commercially available treatment patient AML . Cytarabine FDA approve commercially available treatment patient AML . The use drug combination investigational . The study doctor explain drug design work . Up 75 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Diagnosis 1 ) AML ( WHO classification definition &gt; /= 20 % blast ) , 2 ) high risk MDS ( define presence 10 % blast ) . 2 . Patients age 18 60 year eligible . Patients older 60 deem fit receive intensive chemotherapy treat physician eligible discussion PI . 3 . In Phase I portion , patient relapse refractory AML/MDS also eligible , per treat physician 's discretion . 4 . For Phase II portion study , patient must chemonaive , i.e . receive prior chemotherapy ( except hydrea one dose araC &lt; /= 2g ) AML MDS . They could receive hypomethylator agent , transfusion , hematopoietic growth factor vitamin . Temporary prior measure apheresis hydrea one dose araC &lt; /= 2g order safely control hyperleucocytosis prior enrollment . 5 . Serum biochemical value follow limit unless consider due leukemia : Creatinine &lt; /= 1.5 mg/dl total bilirubin &lt; /= 1.5 mg/dL , unless increase due hemolysis congenital disorder transaminase ( SG PT ) &lt; /= 2.5 x ULN . 6 . Ability take oral medication . 7 . Ability understand provide sign informed consent . 8 . Baseline test ejection fraction must &gt; /= 50 % . 9 . Performance status &lt; 3 , unless directly related disease process determine Principal Investigator . 1 . Subjects APL . 2 . Any coexist medical condition judgment treat physician likely interfere study procedure result . 3 . Nursing woman , woman childbearing potential positive urine pregnancy test , woman childbearing potential willing maintain adequate contraception ( birth control pill , IUD , diaphragm , abstinence , condom partner ) entire course study . Women childbearing potential ( WOCBP ) must use appropriate method ( ) contraception . WOCBP use adequate method avoid pregnancy 23 week ( 30 day plus time require nivolumab undergo five halflives ) last dose investigational drug . Women childbearing potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start nivolumab . Women must breastfeed . 4 . Continued : Men sexually active WOCBP must use acceptable birth control method . Acceptable birth control method include : oral injectable hormonal birth control , transuterine device ( IUDS ) , double barrier method ( example condom combination spermicide ) . Men receive nivolumab sexually active WOCBP instruct adhere contraception period 31 week last dose investigational product Women childbearing potential ( ie , postmenopausal surgically sterile well azoospermic men require contraception . 5 . Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . 6 . History cardiac ventricular arrhythmia require antiarrhythmic therapy within past 3 month . 7 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 8 . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . 9 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . 10 . Active clinically serious uncontrolled infection &gt; CTCAE Grade 2 uncontrolled antibiotic . 11 . Patients exclude active , know suspected autoimmune disease . Subjects permit enroll vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger . 12 . Patients exclude know positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicate acute chronic infection . 13 . Patients exclude known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . 14 . History allergy study drug component . 15 . Prior immune checkpoint target drug ( e.g. , anti PD1 , PDL1 , antikir , anti CD137 ... etc )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>High-risk</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>BMS-936558</keyword>
	<keyword>Opdivo</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Solu-Medrol</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Depo-Medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>